US Patent

US7973040 — Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors

Method of Use · Assigned to Istituto di Ricerche di Biologia Molecolare P Angeletti SpA · Expires 2029-07-24 · 3y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of macrocyclic quinoxaline compounds as inhibitors of the hepatitis C virus (HCV) NS3 protease.

USPTO Abstract

The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.

Drugs covered by this patent

Zepatier (ELBASVIR) · Merck & Co.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1813`	—	Zepatier

Patent Metadata

Patent number: US7973040
Jurisdiction: US
Classification: Method of Use
Expires: 2029-07-24
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.